Hinge Health Inc

HNGE has broken the multi-touch support cluster and confirmed a Stage 3 distribution phase, with price now below declining EMAs and support acting as resistance. The short-term downtrend and lack of mean-reversion signals favor selling into the current weakness. We will sell now on this breakdown, while a sustained reclaim above the 9EMA/20EMA zone or the former support near $88.60–$89.20 would invalidate this bearish bias.

• ↑Revenue rose 53% YoY to $213M in Q2 ’26; operating margin expanded to 29%.
• ↑Generated $100M in free cash flow (47% margin), funding $300M repurchase.
• ↓Forward P/E of 67.7x suggests limited upside.